Literature DB >> 30552108

Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in CSAD/lnc-ITGB7-1 on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes.

Yumiko Kawabata1, Nao Nishida2,3, Takuya Awata4, Eiji Kawasaki5, Akihisa Imagawa6, Akira Shimada7, Haruhiko Osawa8, Shoichiro Tanaka9, Kazuma Takahashi10, Masao Nagata11, Hisafumi Yasuda12, Yasuko Uchigata13, Hiroshi Kajio14, Hideichi Makino15, Kazuki Yasuda16, Tetsuro Kobayashi17, Toshiaki Hanafusa18, Katsushi Tokunaga19, Hiroshi Ikegami20.   

Abstract

The first genome-wide association study of fulminant type 1 diabetes was performed in Japanese individuals. As previously reported using a candidate gene approach, a strong association was observed with multiple single nucleotide polymorphisms (SNPs) in the HLA region, and the strongest association was observed with rs9268853 in the class II DR region (P = 1.56 × 10-23, odds ratio [OR] 3.18). In addition, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level (P = 7.58 × 10-9, OR 1.96). Fine mapping of the region revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value (P = 4.60 × 10-9, OR 1.97 [95% CI 1.57-2.48]). The risk allele of rs3782151 is a cis expression quantitative trait locus for ITGB7 that significantly increases the expression of this gene. CSAD/lnc-ITGB7-1 was found to be strongly associated with susceptibility to fulminant, but not classical, autoimmune type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30552108     DOI: 10.2337/db18-0314

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  Molecular Signatures of Diabetic Kidney Disease Hiding in a Patient with Hypertension-Related Kidney Disease: A Clinical Pathologic Molecular Correlation.

Authors:  Jiten Patel; Jose R Torrealba; Emilio D Poggio; Jack Bebiak; Charles E Alpers; Stephanie M Grewenow; Robert D Toto; Michael T Eadon
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-15       Impact factor: 10.614

2.  Co-expression Network Revealed Roles of RNA m6A Methylation in Human β-Cell of Type 2 Diabetes Mellitus.

Authors:  Cong Chen; Qing Xiang; Weilin Liu; Shengxiang Liang; Minguang Yang; Jing Tao
Journal:  Front Cell Dev Biol       Date:  2021-05-18

3.  Japanese Type 1 Diabetes Database Study (TIDE-J): rationale and study design.

Authors:  Daisuke Chujo; Akihisa Imagawa; Kazuki Yasuda; Norio Abiru; Takuya Awata; Tomoyasu Fukui; Hiroshi Ikegami; Eiji Kawasaki; Takeshi Katsuki; Tetsuro Kobayashi; Junji Kozawa; Kan Nagasawa; Hiroshi Ohtsu; Yoichi Oikawa; Haruhiko Osawa; Akira Shimada; Masayuki Shimoda; Kazuma Takahashi; Kyoichiro Tsuchiya; Tetsuro Tsujimoto; Hisafumi Yasuda; Toshiaki Hanafusa; Hiroshi Kajio
Journal:  Diabetol Int       Date:  2021-09-06

4.  Performance of whole-genome promoter nucleosome profiling of maternal plasma cell-free DNA for prenatal noninvasive prediction of fetal macrosomia: a retrospective nested case-control study in mainland China.

Authors:  Qianwen Lu; Zhiwei Guo; Jun Zhang; Ke Wang; Qi Tian; Siping Liu; Kun Li; Cailing Xu; Caimin Li; Zenglu Lv; Zhigang Zhang; Xuexi Yang; Fang Yang
Journal:  BMC Pregnancy Childbirth       Date:  2022-09-10       Impact factor: 3.105

5.  Identification of candidate biomarkers and therapeutic agents for heart failure by bioinformatics analysis.

Authors:  Vijayakrishna Kolur; Basavaraj Vastrad; Chanabasayya Vastrad; Shivakumar Kotturshetti; Anandkumar Tengli
Journal:  BMC Cardiovasc Disord       Date:  2021-07-04       Impact factor: 2.298

Review 6.  β-Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetes.

Authors:  Hiroshi Ikegami; Naru Babaya; Shinsuke Noso
Journal:  J Diabetes Investig       Date:  2021-06-16       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.